The collaboration is designed to discover and develop clinical candidates for molecular adhesive degraders that are Biogen’s priority targets. The collaboration leverages Neomorph’s leading molecular adhesive discovery platform and Biogen’s deep expertise in Alzheimer’s disease, rare diseases and immune diseases.
CAMBRIDGE, Mass. and SAN DIEGO, Calif., Oct. 29, 2024 (Globe Newswire) — Biogen, Inc. (Nasdaq: BIIB) and Neomorph are partnering to discover and develop molecular adhesive degraders for priority targets in Alzheimer’s disease. We announced a research partnership aimed at , rare neurological and immune diseases.
As part of the collaboration, the companies aim to utilize Neomorph’s proprietary molecular adhesive discovery platform to accelerate the identification and validation of novel small molecule therapeutic molecular adhesive disintegrators. Small molecule proteolytic agents have been shown to effectively treat difficult targets with pharmacology distinct from traditional inhibitors. Pursuing innovative solutions aimed at modulating protein levels through targeted degradation holds promise for the treatment of complex neurological, immunological, and rare diseases. The collaboration leverages Neomorph’s research strengths in targeted protein degradation and Biogen’s deep scientific expertise and drug development capabilities.
“As part of our modality-agnostic research strategy, Biogen is committed to investing in new approaches to uncover previously elusive biological targets,” said Biogen’s Principal Investigator. , said Dr. Jane Grogan. “This collaboration with Neomorph reflects our approach to combining in-house drug development expertise with cutting-edge external innovation to create clinically meaningful treatments for patients.”
“Neomorph’s molecular adhesive disassembly platform represents a unique approach to drug discovery,” said Phil Chamberlain, DPhil, co-founder, president, and CEO of Neomorph. “We are pleased to partner with Biogen, a leader in Alzheimer’s disease, rare diseases and immune diseases, to explore the potential of our technology in addressing some of the most difficult and valuable targets in these fields. Masu.”
Under the terms of the agreement, Biogen and Neomorph will collaborate to identify, validate and optimize small molecule adhesive degraders against several high-priority targets, with Biogen providing potential for further development and commercialization. Promote clinical candidates towards the future. Neomorph will receive an upfront payment and will be eligible to receive contingent milestone payments on a per-target basis as the collaboration progresses through various stages. These include certain preclinical milestones to be paid in the near term and certain clinical, regulatory, commercial and sales milestones expected to occur later this decade and beyond, with total consideration up to That’s $1.45 billion. Biogen will reimburse Neomorph for certain research and development costs. Neomorph is also eligible to receive future royalties in the mid-single digit to low double digit range.
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines that transform patients’ lives and create value for our shareholders and communities. We apply our deep understanding of human biology and leverage a variety of modalities to advance first-in-class treatments and treatments that deliver superior results. Our approach is to take bold risks while balancing investment returns to achieve long-term growth.
We periodically post information we believe is important to investors on our website (www.biogen.com). Follow us on social media including Facebook, LinkedIn, X, and YouTube.
About Neomorph
Neomorph is a biotechnology company that solves critical problems in human health through the discovery and development of innovative new drugs against “undruggable” targets. Neomorph was founded in 2020 and is venture-backed by Deerfield Management Company.
Neomorph’s team is comprised of industry-leading experts in protein degradation and molecular adhesives with a track record of breakthrough discoveries in this field. Neomorph’s team is committed to providing leadership in advancing the science and technology of molecular adhesive drug discovery while driving a pipeline of projects through clinical development.
Neomorph is headquartered in San Diego, California. For more information, visit www.neomorph.com and follow us on LinkedIn.
Biogen Safe Harbor
This press release contains forward-looking statements, including statements regarding our strategy and plans. the potential and expectations of our commercial business and pipeline programs; Capital allocation and investment strategies. Clinical development programs, clinical trials, data readout and presentation. Possibility of molecular adhesive decomposers. Regulatory discussions, submissions, applications, and approvals. We also discuss the potential benefits, safety, and effectiveness of our collaboration with Neomorph. These forward-looking statements include “aims,” ”expects,” “believes,” “may,” “estimates,” “expects,” “predicts,” “goals,” “intendions,” It may be accompanied by words such as “will” or “may”. , “plan,” “potential,” “potential,” “outlook,” “intend,” “would” and other words and terms of similar meaning. The development and commercialization of pharmaceutical products involves high risks, and only a small number of research and development programs lead to commercialization of products. Results from early-stage clinical trials may not be indicative of the complete results or results of later-stage or larger-scale clinical trials and do not guarantee regulatory approval. Do not place undue reliance on these statements.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including dependence on sales of our products. uncertainty of the long-term success of developing, licensing or obtaining other product candidates or additional indications for existing products; unable to compete effectively; our inability to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; difficulties in obtaining and maintaining adequate coverage, pricing and reimbursement for our products; our dependence on collaborators and other third parties for product development, regulatory approval, commercialization and other aspects of our business that are beyond our complete control; risks associated with current and potential future health care reforms; risks associated with the commercialization of biosimilars; failure to acquire, protect, or enforce our data, intellectual property, or other proprietary rights; and the risks and uncertainties associated with intellectual property claims and challenges.
These statements speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statements.
